Population-based 10-year event-free survival after radical prostatectomy for patients with prostate cancer in British Columbia

Authors

  • Michael Peacock
  • Jill Quirt
  • W James Morris
  • Alan So
  • Charmaine Kim Sing
  • Tom Pickles
  • Scott Tyldesley Vancouver Centre, British Columbia Cancer Agency

DOI:

https://doi.org/10.5489/cuaj.3288

Abstract

Introduction: We determined (1) the 10-year survival outcomes after radical treatment of prostate cancer and (2) the 10-year eventfree survival following radical prostatectomy (RP) at a populationlevel in British Columbia (BC), Canada.

Methods: We identified all men with a new diagnosis of prostate cancer in BC between 1999 and 2000. Those treated with RP, external beam radiotherapy (EBRT) or brachytherapy (BT) were identified. Overall survival, and prostate cancer specific survival (PCSS) were calculated from diagnosis using the Kaplan-Meier method. For those men treated with RP, we calculated the 10-year event-free survival (freedom from salvage EBRT or androgen ablation, or death from prostate cancer). Reasons for initiating androgen therapy were unknown and may include symptomatic metastatic disease or asymptomatic biochemical recurrence. An important limitation was the absence of prostate-specific antigen data for staging or follow-up.

Results: Among 6028 incident cases, RP was the curative-intent treatment within 1 year in 1360 (22.6%) patients, EBRT in 1367 (22.7%), and BT in 357 (5.9%). The 10-year PCSS was 98% for RP, 95% for EBRT and 98% for BT (log rank p < 0.0001). The 10-year overall survival was 87%. The 10-year event-free survival for those treated with RP was 79% and varied with Gleason grade: 87%, 74%, and 52% for Gleason 2–6, 7, and 8-10, respectively (p < 0.0001).

Conclusions: This population-based study provides outcomes which can inform patient decision-making and provide a benchmark to which other therapies can be compared. Event-free rates for patients treated with RP vary with Gleason score. There is room for improvement in the outcomes of patients with high Gleason score treated with RP.

Downloads

Download data is not yet available.

Downloads

Published

2015-12-14

How to Cite

Peacock, M., Quirt, J., Morris, W. J., So, A., Sing, C. K., Pickles, T., & Tyldesley, S. (2015). Population-based 10-year event-free survival after radical prostatectomy for patients with prostate cancer in British Columbia. Canadian Urological Association Journal, 9(11-12), 409–13. https://doi.org/10.5489/cuaj.3288

Issue

Vol. 9 No. 11-12 (2015): CUAJ December

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.